Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.
Angeles Alvarez Secord, MD, a gynecologic oncologist at Duke Cancer Center, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula).
It’s important to be aware of all new studies that are being presented, says Secord. Three studies of PARP inhibitors were presented at the 2019 European Society for Medical Oncology Congress at the same time, which gave physicians the ability to evaluate results altogether. Now all of the agents are FDA approved for the same indication, so these data are important to evaluate to determine their role in ovarian cancer
Secord found it very exciting to see all 3 trials presented at the same meeting because she and other physicians could examine the differences between them in terms of patient populations, drug combinations, and the drugs that were used. She was able to synthesize the information to determine the best treatment for her patients.
The bottom-line is that in select patient populations, specifically those with a BRCA1/2 somatic or germline mutation, there appears to be benefit with PARP inhibitors, particularly based on the data from the PRIMA trial.
<< View more resources and information regarding ovarian cancer
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More